Assessing the Efficacy of Novel Anticoagulant in Atrial Fibrillation
Clinical studies require meticulous planning, with multiple endpoints used to assess a drug’s potential benefits and side effects. The increasing complexity has led to collaboration with Contract Research Organizations (CROs), providing specialized support in various phases of drug development. The U.S. CRO market shows steady growth, driven by the demand for expertise.
KEY FACTS:
- Objective: This randomized controlled trial evaluates the effectiveness and safety of a newly developed anticoagulant in preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation. The study aims to compare the new anticoagulant with standard-of-care anticoagulation therapy.
- Eligibility Criteria: Adults diagnosed with non-valvular atrial fibrillation and at moderate to high risk of stroke may be eligible to participate.
- Location: Cardiology departments of participating hospitals worldwide.
Previous Studies:
Clinical studies require meticulous planning, with multiple endpoints used to assess a drug’s potential benefits and side effects. The increasing complexity has led to collaboration with Contract Research Organizations (CROs), providing specialized support in various phases of drug development. The U.S. CRO market shows steady growth, driven by the demand for expertise.
Principal Investigator
- 2015 NOVONORDISK: 3995 TYPE1 DIABETICINSULINTRIAL
- 2014 SHIONOGI: 9232 NALDEMEDINETOOIC
- 2013GENKYOTEXGKT137831 TOTYPE2 DIABETES& ALBUMINURIA
- 2013 FERRIN: 000070 LUTREPULSEOMNIPOD
- 2013 ASTRAZENECA: MEDI-563 BENRALIZUMABTO
Be The First One To Know About New Upcoming Studies.
If you’re ready to take your knowledge to the next level and be ahead of the curve, join us today. Be the first one to know about new upcoming studies and embark on a journey of continuous learning, growth, and exploration. Your future of discovery starts here.
